
Pharma giants want to crash the skincare party. It will be a long haul.
Cipla Ltd, Glenmark Pharmaceuticals Ltd and Emcure Pharmaceuticals Ltd, which have a presence in the dermatology or skin diseases segment, are expanding with sunscreens, moisturisers and serums, products that don't need a prescription.
'There is an evident surge in cosmo-derma products in India, driven by the consumer's need for a trustworthy science-backed solution that is efficacious and affordable," Shivam Puri, managing director and chief executive of Cipla Health Ltd, Cipla's consumer-focused unit, told Mint.
Cosmo-derma products or 'cosmoceuticals' fall somewhere between traditional cosmetics and pharmaceuticals, offering active ingredients that target specific skin concerns, but need not be prescription-grade drugs.
'The space has become extremely cluttered, and consumers are increasingly turning to brands with clinically backed claims, dermatologist endorsements, and proven efficacy," Puri added.
However, pharma companies have a long way to climb.
India's beauty and personal care market is poised to grow to $34 billion by 2028 from $21 billion in 2023, with the skincare category growing the fastest, at a compound annual growth rate of 13%, according to retailerNykaa's beauty trends report 2024.
In comparison, cosmo-derma sales by pharmaceutical companies in India was ₹4,851 crore (about $565 million) as of June, show data by pharma intelligence platform Pharmarack. The cosmo-derma sector, however, grew at a faster 17% CAGR over the previous 5 years.
Pharmaceutical companies also have to contend with consumer goods giants in the skincare space. Hindustan Unilever Ltd acquired a 90.5% stake in Minimalist earlier this year, valuing the Jaipur-based online skincare and haircare brand at ₹2,955 crore (about $345 million).
A battle in the beauty arena—key points
A clinical approach
Last year, responding to the growing demand for skincare products, Emcure Pharmaceuticals launched Emcutix Biopharmaceuticals Ltd to expand its derma business with a focus on offerings such as moisturisers built with multi-layer fatty acid emulsion technology and a non-invasive topical treatment for skin tightening.
'The line between medicine and skincare continues to blur," said Sathya Narayanan, CEO of Emcutix. 'We have seen that people are willing to invest more when they know a product is non-comedogenic, fragrance-free, and backed by science."
Glenmark, among India's largest dermatology players, is leveraging its research and development capabilities, manufacturing facilities, and its distribution network to expand in the over-the-counter (OTC) or non-prescription skincare products.
'Our model gives us the agility to bring dermatologist-trusted, high-efficacy formulations to market at a price point that's accessible," said Alok Malik, president of Glenmark's India formulations business.
'While startups have brought agility, which has benefited the entire category, what sets us apart as a pharmaceutical brand, is our clinical depth, long-standing dermatologist trust, and a robust safety profile," Malik added.
India's beauty brands battle hard in a crowded market
Torrent Pharmaceuticals Ltd, which has an established presence in the dermatology segment, in 2022 acquired skincare product maker Curatio Healthcare for ₹2,000 crore, adding leading brands Tedibar and Atogla to its kitty.
Despite their miniscule presence, pharma companies stand a good chance to build brands in the non-prescription skincare market, said Vishal Manchanda, senior vice president of institutional research at Systematix Group, a management advisory.
'They are better poised because they have a better bandwidth for clinical trials, and pharmaceutical understanding also helps in creating claims and doing studies," he said.
What's driving demand?
Beauty brands like Canada's The Ordinary and Minimalist have popularised the active ingredients approach to skincare, and compounds like retinol, hyaluronic acid, and niacinamide have become part of daily parlance, especially among young users.
'A lot of this [demand] has been powered because of social media and influencer-led brand activities which talked about ingredients and percentages, etc.," said Dr. Chytra Anand. 'For the longest time, influencer-led activity played a big role in purchase, not just information. Now, influencer activities have become more informational."
The Bengaluru-based cosmetic dermatologist said she's seeing a growth in patients coming for regular skin health checkups and recommendations the past 3-4 years, as opposed to patients seeking treatment for pre-existing skin and hair conditions.
'It's really been the OTC brands that went out and did a lot of marketing and created this awareness. Now going to a doctor, be it a dermatologist or an aesthetic doctor who sees skincare problems, has become normal," Dr. Anand said.
Mint spoke with a number of users, largely women in their 20s and 30s who have switched from cosmetic skincare brands to dermatologist-recommended cosmo-derma products for concerns like acne-prone skin and sun protection.
'I believe in science-backed products more than hyped beauty PR products," said Arunima Joshua. The Mumbai-based freelance writer and media professional added that she had tried Korean skincare products and other well-known brands before switching to products recommended by a dermatologist.
However, Joshua, who writes on lifestyle, maintained that the shift towards dermatologist recommendations is slow, with influencer-backed marketing pushing people to self-prescribe.
The real differentiator
For such people, dermatologists cautioned against the misuse of compounds such as retinol that are sold by cosmetics brands.
'There is no regulation in the Indian market… people can buy retinol over the counter and not need a prescription," said Mumbai-based dermatologist Dr. Sagar Gujjar.
Retinol, or vitamin A1, is a popular skincare ingredient used to reduce wrinkles and enlarged pores. But users need to know the right percentage and efficacy suitable for them, said Dr. Anand, adding that products by pharmaceutical companies are more reliable for such use.
'If somebody has never used a basic cleanser, they are not going to start off with a clinically backed cleanser," added Dr. Anand.
However, a younger cohort of users in their 20s and 30s is likely to be well-researched and opt for a clinical grade product. 'They equate pharma and derm-related, doctor-related to high-trust value, high potency, high efficacy," Dr Anand said.
'The real differentiator is clinical depth and trust," added Malik of Glenmark.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
22 minutes ago
- New Indian Express
Around 30 per cent of Indians at risk of obesity: CCMB Study
HYDERABAD: Long-term tracking of thousands of healthy Indian individuals has revealed that 25 per cent to 30 per cent became obese by adulthood, even though they showed no signs of the condition at the beginning. This finding is part of a global study that offers new genetic insights into obesity and introduces a polygenic risk score (PRS) capable of predicting the likelihood of developing obesity as early as age five. The study involved over 600 scientists across 500 institutions, including researchers from Hyderabad-based CSIR-CCMB. Led by senior geneticist Dr. Giriraj Ratan Chandak, CSIR-CCMB contributed to ensuring that the genetic data from Indian participants reflected South Asian diversity. Dr. Chandak told TNIE, 'The study included four Indian cohorts, mainly from Mysore, Mumbai, and Pune, ranging from 2,200 to over 20,000 individuals, many of whom have been followed for nearly two decades. The long-term data allowed researchers to assess how genetics and lifestyle together influence obesity progression over a lifetime.' The study also found that individuals with a higher genetic risk are more prone to obesity but tend to respond better to lifestyle interventions, although they may regain weight more quickly when those interventions are discontinued.


Time of India
an hour ago
- Time of India
Private banks' yields on advances dip on faster rate transmission
Private banks recorded a sharper fall, primarily because they have a higher share of loans priced on the external benchmark linked rate (EBLR) in their portfolio. EBLR adjusts more rapidly to policy changes than the marginal cost of funds-based lending rate (MCLR), the benchmark that most PSB loans are linked to. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MUMBAI: Private sector banks have been quicker than their public sector counterparts in passing on the Reserve Bank of India's policy rate cuts to on loans for private banks dropped by 20-83 basis points (bps) in the quarter ended June 30 from three months prior. For public sector banks (PSBs), the decline was limited to 2-22 bps, based on the quarterly financial statements of central bank has cut policy repo rate by 100 basis points since February, with three-fourths of this reduction being done in the April-June banks recorded a sharper fall, primarily because they have a higher share of loans priced on the external benchmark linked rate (EBLR) in their portfolio. EBLR adjusts more rapidly to policy changes than the marginal cost of funds-based lending rate (MCLR), the benchmark that most PSB loans are linked 87% of private banks' floating rate loans are on EBLR as of the end of March 2025, compared with 46% for state-run banks, according to the RBI data. The share of loans linked to MCLR, where transmission works with lag effect and depends on the fall in incremental cost of deposits, is 12% for private banks and 49% for banks also saw a 0-20 bps decline in deposit costs during the quarter, whereas PSBs reported a relatively modest drop of 6-15 bps, the June-quarter numbers HDFC Bank , the cost of funds fell by about 10 bps, while loan yields declined by 20-22 bps. About 70% of the loan book of the country's largest private sector bank is linked to EBLR; the remaining is MCLR-based."These (EBLR-based) are floating-rate loans, so they reprice faster than the cost of funds," said HDFC Bank chief financial officer Srinivasan Vaidyanathan. "We manage our cost of funds by competitively pricing our savings and time deposits. The market hasn't fully priced in the 100-bps reduction in the policy rate between February and June. New deposit renewals will come in at lower rates." ICICI Bank reported a 33-bps sequential drop in loan yields to 9.53%. Axis Bank 's cost of funds came in at 5.39%, down 11 bps quarter-on-quarter and five bps year-on-year. The cost of deposits declined by 12 bps, while loan spreads narrowed by 13 bps."We've demonstrated disciplined increases in cost of funds over the last eight quarters," Axis Bank managing director and chief executive Amitabh Chaudhry said. "Our confidence in the franchise has allowed us to take proactive steps on savings and term deposit rates, resulting in an 11-bps sequential drop in cost of funds." Yes Bank saw its loan yields decline by 20 bps sequentially to 9.9%, with a corresponding fall in deposit costs to 5.9%. The bank's overall cost of funds fell by 10 bps to 6.3%. "The rate cut we implemented on savings account balances helped us align our deposit costs with the decline in loan yields," MD and CEO Prashant Kumar said, adding: "While we expect continued pressure on loan yields due to the repo rate cut, our focus remains on mitigating the impact."According to Saurabh Bhalerao, associate director at CareEdge Ratings, while private banks are seeing upfront pressure on margins mainly because of EBLR loans and competition, it will play out over the next two-three quarters for PSBs as MCLR rates fall with a lag. "Banks would try to make up for the pressure on NIMs (net interest margins) by managing the spreads as well as the cost of funds," he said.


Mint
an hour ago
- Mint
Bosch Layoffs: German autoparts maker to cut 1,100 jobs; assembly line and back-office roles at risk
Bosch Layoffs: German automotive components makerBosch announced its plans to cut 1,100 jobs at its Southern Germany-based plant on Tuesday, 22 July 2025, and disclosed that this move will affect one-tenth of the workers at the site, reported the news agency AFP. Advertisement This layoff will affect people who are involved in the site's assembly line as well as in back-office roles, reported the news agency, citing the German autoparts maker. 'The European market for steering systems is driven by price and hard fought with new suppliers,' said Bosch's electronics chief, Dirk Kress, amid the rising competition from the Chinese manufacturers in recent years. German car manufacturers have been struggling with this issue in recent times as the Asian nation contests for market share. 'The required cuts are not easy, but they are essential to secure the future of the site,' he said, according to the news agency's report. Losing the 'competitive' edge According to the agency report citing the autoparts maker, steering system sales were declining partly due to the sluggish uptake of electric vehicles. Advertisement Also Read | Stocks to buy under ₹100: Experts recommend two shares to buy tomorrow 'Manufacturing steering systems at the Reutlingen site is no longer competitive,' said Bosch, highlighting that the plant would now focus on manufacturing semiconductors. However, the company did not say whether the job cuts would involve compulsory redundancies or rely on voluntary measures such as early retirement. Other automotive suppliers like Schaeffler and Continental have made layoffs in the past year, while sports car maker Porsche last Friday warned workers of a 'serious situation' amid collapsing demand in China. In November 2024, Bosch also announced a 5,500-employee layoff across the company, according to the agency report. Bosch is a listed company in the Indian stock market, and the shares closed 1.37% lower at ₹37,750 after Tuesday's stock market session, compared to ₹38,320 at the previous market close. Advertisement Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of Mint. We advise investors to check with certified experts before making any investment decisions.